Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201206100 Principal Investigator: Bartlett, Nancy
Title: A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton’s Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy
Phase: II Disease Site: Non-Hodgkin's Lymphoma
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu
Description:
Ibrutinib is a drug that is being tested to see if it may be useful in treating Mantle Cell Lymphoma that has come back after previous treatment(s). The purpose of this study is to assess the effects (both good and bad) of ibrutinib in Mantle Cell Lymphoma and whether the Lymphoma responds to this treatment.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)